Evenity (Romosozumab) and Pregabalin Interaction: Safety, Risks, and Clinical Guidance

Why This Drug Combination Comes Up in Clinical Practice

Patients prescribed romosozumab for severe osteoporosis frequently have comorbid pain syndromes. That overlap is not coincidental. Osteoporosis affects an estimated 10.2 million Americans aged 50 and older according to the National Health and Nutrition Examination Survey data published through the CDC [1], and neuropathic pain conditions like diabetic peripheral neuropathy and postherpetic neuralgia are common in the same age demographic. Pregabalin (brand name Lyrica) is one of the most widely prescribed medications for these neuropathic pain conditions, as well as fibromyalgia and generalized anxiety disorder in some regions.

Romosozumab received FDA approval in April 2019 [2] specifically for postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture or multiple risk factors, or patients who have failed other osteoporosis therapies. Its 12-month treatment course creates a defined window during which comedication review is particularly relevant. Clinicians prescribing both agents need clarity on whether the combination poses any pharmacologic hazard beyond what each drug carries alone.

Pharmacokinetic Profile: No Metabolic Overlap

The two drugs occupy entirely separate metabolic pathways, which eliminates the most common source of drug interactions. Romosozumab is a humanized IgG2 monoclonal antibody that binds sclerostin. Like all therapeutic monoclonal antibodies, it is degraded through intracellular proteolysis into amino acids and small peptides [2]. It does not interact with cytochrome P450 enzymes, UDP-glucuronosyltransferases, or drug transporters such as P-glycoprotein or organic anion transporters. The FDA prescribing information for Evenity [2] does not list any pharmacokinetic drug interactions because none have been identified.

Pregabalin is equally uninvolved in hepatic drug metabolism. According to the FDA label for Lyrica [3], pregabalin undergoes negligible metabolism in humans. Approximately 90% of the administered dose is recovered unchanged in urine. It is not bound to plasma proteins. It does not inhibit or induce CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4. No displacement interactions with protein-bound drugs are expected.

The bottom line is straightforward. These two drugs cannot interfere with each other's absorption, distribution, metabolism, or elimination through any known pharmacokinetic mechanism.

The Real Concern: Fall Risk as a Pharmacodynamic Interaction

Where the interaction becomes clinically meaningful is not in the bloodstream but in the patient's daily functioning. Pregabalin causes dose-dependent central nervous system depression. In the key trials for diabetic peripheral neuropathy, dizziness occurred in 29% of patients on pregabalin 300 mg/day and 35% on 600 mg/day, compared to 8% on placebo. Somnolence rates followed a similar pattern: 13-22% versus 4% on placebo, per the Lyrica prescribing information [3].

For a patient whose bones are fragile enough to warrant romosozumab, a fall is not merely inconvenient. It can be catastrophic. The ARCH trial (N=4,093), which compared romosozumab to alendronate in postmenopausal women with osteoporosis and prior fracture, demonstrated that this population carries a 24-month cumulative clinical fracture incidence of approximately 9.7% even with active treatment [4]. Any medication that increases the probability of falling amplifies fracture risk in a population already defined by skeletal fragility.

A 2016 systematic review and meta-analysis published in PLOS ONE found that pregabalin use was associated with a significantly increased risk of falls and fall-related injuries, with particular relevance in elderly populations taking concurrent CNS depressants [5]. The American Geriatrics Society Beers Criteria [6] lists pregabalin among medications to use with caution in older adults due to CNS effects that may increase fall risk.

"Medications that impair balance and alertness should be carefully reviewed in any patient being treated for severe osteoporosis," states the Endocrine Society's 2020 clinical practice guideline on pharmacological management of osteoporosis [7]. This applies directly to the romosozumab-pregabalin pairing.

Romosozumab's Cardiovascular Boxed Warning: A Separate Risk Layer

Romosozumab carries a boxed warning for major adverse cardiovascular events [2]. In the ARCH trial, the romosozumab-to-alendronate group had a higher incidence of adjudicated cardiovascular serious adverse events (2.5%) compared to the alendronate-to-alendronate group (1.9%) during the first 12 months [4]. The FDA label states that romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year.

Pregabalin does not carry a known cardiovascular interaction with romosozumab. It does not prolong QTc or increase thrombotic risk. Peripheral edema occurs in 6-16% of pregabalin-treated patients [3], and while edema alone does not constitute a cardiovascular event, it may complicate monitoring in patients with pre-existing heart failure. Clinicians managing patients on both medications should document baseline cardiovascular status and remain attentive to new-onset edema or fluid retention symptoms during the romosozumab treatment window.

Bone Metabolism Considerations: Does Pregabalin Affect Bone?

This question warrants scrutiny. Pregabalin itself is not classified as a medication that directly causes bone loss. It does not appear on the standard lists of drugs associated with secondary osteoporosis (which include glucocorticoids, aromatase inhibitors, GnRH agonists, and certain anticonvulsants like phenytoin and carbamazepine).

The distinction matters. Enzyme-inducing anticonvulsants (phenytoin, carbamazepine, phenobarbital) accelerate vitamin D catabolism through CYP3A4 and CYP24A1 induction, leading to reduced calcium absorption and increased fracture risk. The American Academy of Neurology and American Epilepsy Society review on bone health in epilepsy patients [8] identified this mechanism as specific to enzyme-inducing agents. Pregabalin is not enzyme-inducing. A 2015 population-based study in the Journal of Bone and Mineral Research confirmed that non-enzyme-inducing anticonvulsants, including gabapentinoids, showed a weaker association with fracture risk than their enzyme-inducing counterparts, though the fall-related mechanism remained relevant [9].

So pregabalin will not pharmacologically counteract romosozumab's anabolic bone effects. The concern remains mechanical, not metabolic. Falls, not drug metabolism, are the threat.

Monitoring Protocol for Concurrent Use

No dose adjustment of either drug is required specifically because of the combination. Romosozumab is administered as two 105 mg subcutaneous injections (total 210 mg) once monthly for 12 doses [2]. That fixed regimen does not change based on concomitant medications.

Pregabalin dosing should be adjusted based on renal function, as it always should be regardless of other medications. The FDA label [3] provides specific creatinine clearance-based dose reductions: patients with CrCl 30-60 mL/min should receive 50% of the normal dose, and those with CrCl 15-30 mL/min should receive 25%. This is standard pregabalin management.

What does change when these drugs are co-prescribed is the intensity of fall-risk monitoring. A practical monitoring approach includes:

Before initiating romosozumab in a patient already on pregabalin:

• Perform a formal fall-risk assessment (Timed Up and Go test, gait speed, or STEADI toolkit from the CDC [10])
• Review the pregabalin dose and assess whether the lowest effective dose is being used
• Document whether the patient has experienced dizziness, somnolence, or balance problems
• Check renal function to confirm appropriate pregabalin dosing

During the 12-month romosozumab course:

• Reassess fall risk at each monthly injection visit
• Ask specifically about new or worsening dizziness
• Monitor for peripheral edema, especially in patients with cardiovascular risk factors
• Check serum calcium, as romosozumab can cause hypocalcemia (ensure adequate calcium and vitamin D supplementation per label)
• Obtain cardiovascular history review at baseline and report any new chest pain or neurological symptoms

Patient Counseling Points

Patients receiving both medications should understand several specific points. First, taking these two drugs together does not create a dangerous chemical reaction in the body. Second, the concern is practical: pregabalin can make you dizzy or drowsy, and when your bones are weak enough to need romosozumab, a fall carries serious consequences.

The National Osteoporosis Foundation (now the Bone Health & Osteoporosis Foundation) recommends environmental fall-prevention measures for all osteoporosis patients, including removing loose rugs, installing grab bars, ensuring adequate lighting, and wearing appropriate footwear [11]. These recommendations carry extra weight for patients on pregabalin.

Patients should also be counseled not to abruptly discontinue pregabalin if they decide the dizziness risk is too high. The FDA label warns that rapid discontinuation can provoke withdrawal symptoms including insomnia, nausea, headache, and diarrhea, with seizures reported in some cases [3]. Any dose reduction should be tapered over a minimum of one week. Gabapentin, the closely related gabapentinoid, could be considered as an alternative with potentially lower abuse liability, though its fall-risk profile is similar.

"Patients on gabapentinoids should be warned about the increased risk of accidental injury and falls, and this counseling should be documented," notes the 2023 updated Beers Criteria from the American Geriatrics Society [6].

Alternative Analgesic Strategies to Reduce Fall Risk

If a patient on romosozumab requires neuropathic pain management but pregabalin-related dizziness is problematic, several alternatives deserve consideration. Duloxetine (Cymbalta), an SNRI approved for diabetic peripheral neuropathy and fibromyalgia, may offer neuropathic pain relief with a different side-effect profile, though it carries its own dizziness risk at 10-17% in trials. Topical lidocaine patches provide localized relief for postherpetic neuralgia without systemic CNS effects. Capsaicin 8% patches (Qutenza) offer another topical option for peripheral neuropathic pain, as reviewed in a Cochrane systematic review [12].

The choice between continuing pregabalin versus switching depends on how well the current regimen controls pain, how severe the fall risk is, and patient preference. For patients whose pain is well controlled on a low pregabalin dose (75-150 mg/day) with minimal dizziness, continuation during the 12-month romosozumab course is reasonable. For patients on higher doses (300-600 mg/day) experiencing balance problems, a supervised taper with transition to an alternative agent may be prudent.

Special Population: Chronic Kidney Disease

Both drugs intersect at the kidney in clinically important ways. Pregabalin requires dose reduction in renal impairment because it is almost entirely renally cleared. Romosozumab does not require renal dose adjustment, but patients with severe renal impairment (CrCl <30 mL/min) are at higher risk for hypocalcemia because of impaired vitamin D activation and secondary hyperparathyroidism. The KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder [13] notes that antiresorptive and anabolic osteoporosis agents should be used cautiously in CKD stages 4-5 due to the complexity of renal osteodystrophy.

In a patient with CKD stage 3 or worse taking both medications, pregabalin accumulation can intensify CNS side effects, compounding fall risk. Confirming that the pregabalin dose matches current estimated GFR is a simple but often overlooked step.

DDI Database Severity Rating

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not flag a direct interaction between romosozumab and pregabalin. This combination does not appear in the FDA Adverse Event Reporting System (FAERS) as a recognized drug interaction pair. The interaction is classified as theoretical/pharmacodynamic rather than established/pharmacokinetic.

This does not mean the combination is risk-free. It means the risk is indirect: pregabalin increases fall probability, and falls in romosozumab-eligible patients increase fracture probability. The absence of a formal DDI classification should not be confused with the absence of clinical relevance.